{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:54:19Z","timestamp":1785430459174,"version":"3.56.0"},"reference-count":0,"publisher":"Cambridge University Press (CUP)","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can. J. Neurol. Sci."],"abstract":"ABSTRACT<\/jats:title>\n \n Introduction:<\/jats:title>\n Cenobamate is a novel anti-seizure medication (ASM) in the alkyl carbamate family with a dual mechanism of action: targeting persistent sodium currents and positively modulating \u03b3-aminobutyric acid type A receptors independent of benzodiazepines. Approved by Health Canada in June 2023, it offers an additional treatment option for seizures. This study\u2019s objective was to review the real-world experience with cenobamate in a Provincial Comprehensive Epilepsy Program, soon after its availability in Canada.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n A retrospective study of all patients prescribed cenobamate from June 2023 to May 2025.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n The study population comprised 36 patients with a median age of 18 years (range: 8\u201323 years). Seizure etiology was structural (\n n<\/jats:italic>\n = 18) and genetic (\n n<\/jats:italic>\n = 13). Prior to starting cenobamate, patients had tried a mean of 10 ASMs. Additionally, 19 (53%) had undergone epilepsy surgery, 3 (8%) had failed the ketogenic diet and 11 (31%) were treated with neuromodulation. Following a mean duration of 10.5 months of treatment with cenobamate, 50% (18\/36) had\n a<\/jats:italic>\n > 50% seizure reduction, and 20% (7\/36) had a 25%\u201350% reduction of seizures. Fourteen percent (5\/38) of patients were seizure-free at the most recent follow-up. The median dose was 200 mg (range: 62.5\u2013400 mg). Eighteen patients (50%) experienced adverse effects (AEs), including dizziness, drowsiness, nausea and vomiting. However, only two patients discontinued cenobamate due to AEs. No patients discontinued cenobamate due to a lack of efficacy.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n This real-world study demonstrates the efficacy and tolerability of cenobamate in patients with highly drug-resistant epilepsy<\/jats:p>\n <\/jats:sec>","DOI":"10.1017\/cjn.2025.10442","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T08:03:41Z","timestamp":1759997021000},"page":"1-6","source":"Crossref","is-referenced-by-count":1,"title":["Initial Experience with Cenobamate for Drug Refractory Epilepsy at a Canadian Pediatric Tertiary Care Center"],"prefix":"10.1017","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4523-5351","authenticated-orcid":false,"given":"Alexander","family":"Freibauer","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04n901w50","id-type":"ROR","asserted-by":"publisher"}],"name":"BC Children\u2019s Hospital, University of British Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3226-438X","authenticated-orcid":false,"given":"Linda","family":"Huh","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04n901w50","id-type":"ROR","asserted-by":"publisher"}],"name":"BC Children\u2019s Hospital, University of British Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary B.","family":"Connolly","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04n901w50","id-type":"ROR","asserted-by":"publisher"}],"name":"BC Children\u2019s Hospital, University of British Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita N.","family":"Datta","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04n901w50","id-type":"ROR","asserted-by":"publisher"}],"name":"BC Children\u2019s Hospital, University of British Columbia"},{"name":"Clinical Associate Professor of Pediatrics, University of British Columbia Pediatric Neurologist and Epileptologist, Program Director Epilepsy Fellowship Program BC Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2025,10,9]]},"container-title":["Canadian Journal of Neurological Sciences \/ Journal Canadien des Sciences Neurologiques"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0317167125104423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T05:57:11Z","timestamp":1763359031000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0317167125104423\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":0,"alternative-id":["S0317167125104423"],"URL":"https:\/\/doi.org\/10.1017\/cjn.2025.10442","relation":{},"ISSN":["0317-1671","2057-0155"],"issn-type":[{"value":"0317-1671","type":"print"},{"value":"2057-0155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]}}}